JP2016527220A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016527220A5 JP2016527220A5 JP2016526504A JP2016526504A JP2016527220A5 JP 2016527220 A5 JP2016527220 A5 JP 2016527220A5 JP 2016526504 A JP2016526504 A JP 2016526504A JP 2016526504 A JP2016526504 A JP 2016526504A JP 2016527220 A5 JP2016527220 A5 JP 2016527220A5
- Authority
- JP
- Japan
- Prior art keywords
- ion
- formula
- represent
- ions
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 trifluoroacetate ion Chemical class 0.000 claims 18
- 229910052739 hydrogen Inorganic materials 0.000 claims 16
- 125000001424 substituent group Chemical group 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 11
- 229910052736 halogen Inorganic materials 0.000 claims 8
- 150000002367 halogens Chemical class 0.000 claims 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 6
- 206010006451 bronchitis Diseases 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 2
- 206010001889 Alveolitis Diseases 0.000 claims 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 2
- 206010037423 Pulmonary oedema Diseases 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 230000000172 allergic effect Effects 0.000 claims 2
- 150000001450 anions Chemical class 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims 2
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims 2
- 150000002500 ions Chemical class 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
- 229940085991 phosphate ion Drugs 0.000 claims 2
- 208000005333 pulmonary edema Diseases 0.000 claims 2
- 229940095064 tartrate Drugs 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- NDOVLWQBFFJETK-UHFFFAOYSA-N 1,4-thiazinane 1,1-dioxide Chemical group O=S1(=O)CCNCC1 NDOVLWQBFFJETK-UHFFFAOYSA-N 0.000 claims 1
- YHIIJNLSGULWAA-UHFFFAOYSA-N 1,4-thiazinane 1-oxide Chemical group O=S1CCNCC1 YHIIJNLSGULWAA-UHFFFAOYSA-N 0.000 claims 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 1
- 206010052613 Allergic bronchitis Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009137 Chronic sinusitis Diseases 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 241000233866 Fungi Species 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 1
- 229940122696 MAP kinase inhibitor Drugs 0.000 claims 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 claims 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 claims 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 208000037062 Polyps Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 239000000808 adrenergic beta-agonist Substances 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 230000003454 betamimetic effect Effects 0.000 claims 1
- 229940006460 bromide ion Drugs 0.000 claims 1
- 230000007883 bronchodilation Effects 0.000 claims 1
- 208000029771 childhood onset asthma Diseases 0.000 claims 1
- 239000000812 cholinergic antagonist Substances 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000890 drug combination Substances 0.000 claims 1
- 229940121647 egfr inhibitor Drugs 0.000 claims 1
- 239000002713 epithelial sodium channel blocking agent Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 244000000013 helminth Species 0.000 claims 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 claims 1
- 229940006461 iodide ion Drugs 0.000 claims 1
- YEESKJGWJFYOOK-IJHYULJSSA-N leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 claims 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 208000037916 non-allergic rhinitis Diseases 0.000 claims 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical group C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 claims 1
- 239000003848 thrombocyte activating factor antagonist Substances 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- KDISMIMTGUMORD-UHFFFAOYSA-N CC(N1CCCCC1)=O Chemical compound CC(N1CCCCC1)=O KDISMIMTGUMORD-UHFFFAOYSA-N 0.000 description 1
- STNWGORSZKGSBT-UHFFFAOYSA-N CCCCN(C=C(C=C1)C(N(C)C)=O)C1=O Chemical compound CCCCN(C=C(C=C1)C(N(C)C)=O)C1=O STNWGORSZKGSBT-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13176480 | 2013-07-15 | ||
| EP13176480.5 | 2013-07-15 | ||
| PCT/EP2014/063959 WO2015007517A1 (en) | 2013-07-15 | 2014-07-01 | Novel tetra- and pentasubstituted benzimidazolium compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016527220A JP2016527220A (ja) | 2016-09-08 |
| JP2016527220A5 true JP2016527220A5 (https=) | 2017-08-10 |
| JP6461133B2 JP6461133B2 (ja) | 2019-01-30 |
Family
ID=48783089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016526504A Active JP6461133B2 (ja) | 2013-07-15 | 2014-07-01 | 新規４置換及び５置換ベンゾイミダゾリウム化合物 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US9126985B2 (https=) |
| EP (1) | EP3022197B1 (https=) |
| JP (1) | JP6461133B2 (https=) |
| WO (1) | WO2015007517A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007079139A2 (en) | 2005-12-28 | 2007-07-12 | Vertex Pharmaceuticals, Inc. | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| EP3022198B1 (en) | 2013-07-15 | 2019-09-11 | Boehringer Ingelheim International GmbH | Novel 5-substituted benzimidazolium compounds |
| TWI735416B (zh) | 2014-10-06 | 2021-08-11 | 美商維泰克斯製藥公司 | 囊腫纖維化症跨膜傳導調節蛋白之調節劑 |
| KR20170063954A (ko) | 2014-10-07 | 2017-06-08 | 버텍스 파마슈티칼스 인코포레이티드 | 낭성 섬유증 막횡단 전도도 조절자의 조정제의 공-결정 |
| EP3245202B1 (en) * | 2015-01-12 | 2020-03-11 | Boehringer Ingelheim International GmbH | Tetrasubstituted benzimidazolium compounds useful in the treatment of respiratory diseases |
| US20170050992A1 (en) * | 2015-08-20 | 2017-02-23 | Boehringer Ingelheim International Gmbh | Novel annelated phenoxyacetamides |
| BR112018002115A2 (pt) * | 2015-08-20 | 2018-09-18 | Boehringer Ingelheim Int | benzamidas aneladas |
| CA2996087A1 (en) * | 2015-08-20 | 2017-02-23 | Boehringer Ingelheim International Gmbh | Annelated phenoxyacetamides |
| WO2017087885A1 (en) | 2015-11-19 | 2017-05-26 | Dana-Farber Cancer Institute, Inc. | Methods of identifying compounds that interfere with erg-driven misguidance of baf complexes in tmprss2-erg driven prostate cancers |
| GB201610854D0 (en) | 2016-06-21 | 2016-08-03 | Entpr Therapeutics Ltd | Compounds |
| GB201619694D0 (en) | 2016-11-22 | 2017-01-04 | Entpr Therapeutics Ltd | Compounds |
| GB201717051D0 (en) | 2017-10-17 | 2017-11-29 | Enterprise Therapeutics Ltd | Compounds |
| US11497752B2 (en) | 2018-01-30 | 2022-11-15 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| GB201808093D0 (en) | 2018-05-18 | 2018-07-04 | Enterprise Therapeutics Ltd | Compounds |
| WO2020081588A1 (en) | 2018-10-17 | 2020-04-23 | Dana-Farber Cancer Institute, Inc. | Swi/snf family chromatin remodeling complexes and uses thereof |
| US12509453B2 (en) | 2019-01-29 | 2025-12-30 | Foghorn Therapeutics Inc. | BRM/BRG1 inhibitors and uses thereof |
| US12384776B2 (en) | 2019-01-29 | 2025-08-12 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| WO2021155264A1 (en) * | 2020-01-29 | 2021-08-05 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| AU2021213811A1 (en) | 2020-01-29 | 2022-07-28 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| US12383555B2 (en) | 2020-05-20 | 2025-08-12 | Foghorn Therapeutics Inc. | Methods of treating cancers |
| US12606553B2 (en) | 2021-03-09 | 2026-04-21 | Foghorn Therapeutics Inc. | Crystalline forms, compositions containing same, and methods of their use |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5250527A (en) * | 1985-10-24 | 1993-10-05 | Smithkline & French Laboratories Limited | Pyridyl containing benzimidazoles, compositions and use |
| US6858615B2 (en) * | 2002-02-19 | 2005-02-22 | Parion Sciences, Inc. | Phenyl guanidine sodium channel blockers |
| US6903105B2 (en) * | 2003-02-19 | 2005-06-07 | Parion Sciences, Inc. | Sodium channel blockers |
| AU2004266704B2 (en) * | 2003-08-18 | 2012-02-23 | Parion Sciences, Inc. | Capped pyrazinoylguanidine sodium channel blockers |
| US7399766B2 (en) * | 2004-08-18 | 2008-07-15 | Parion Sciences, Inc. | Soluble amide & ester pyrazinoylguanidine sodium channel blockers |
| US7807834B2 (en) * | 2005-08-03 | 2010-10-05 | Parion Sciences, Inc. | Capped pyrazinoylguanidine sodium channel blockers |
| JP2008110935A (ja) * | 2006-10-30 | 2008-05-15 | Kowa Co | ２−フェニルベンゾイミダゾール誘導体を有効成分とするｓｔａｔ６活性化阻害剤 |
| CA2727196A1 (en) * | 2008-06-10 | 2009-12-17 | Novartis Ag | Organic compounds |
| WO2011079087A1 (en) | 2009-12-23 | 2011-06-30 | Glaxo Group Limited | Enac blockers |
-
2014
- 2014-07-01 EP EP14734477.4A patent/EP3022197B1/en active Active
- 2014-07-01 JP JP2016526504A patent/JP6461133B2/ja active Active
- 2014-07-01 WO PCT/EP2014/063959 patent/WO2015007517A1/en not_active Ceased
- 2014-07-14 US US14/330,021 patent/US9126985B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016527220A5 (https=) | ||
| JP2016534088A5 (https=) | ||
| JP2018529657A5 (https=) | ||
| JP2016532677A5 (https=) | ||
| ES2292988T3 (es) | Derivados de nicotinamida utiles como inhibidores de pde4. | |
| JP2014534222A5 (https=) | ||
| HRP20171614T1 (hr) | Heterociklički spojevi, lijekovi koji sadrže te spojeve, njihova primjena i postupci za njihovu proizvodnju | |
| HRP20191339T1 (hr) | Novi anelirani fenoksiacetamidi | |
| UA104997C2 (uk) | Аміди азотвмісних насичених гетероциклів та 3,5-діаміно-6-хлор-2-піразинкарбонової кислоти як лікарський засіб | |
| JP2012500260A5 (https=) | ||
| JP2011162556A5 (https=) | ||
| JP2005516067A5 (https=) | ||
| BR112021022099A2 (pt) | Derivados de amino quinazolina como inibidores de p2x3 | |
| JP2017513836A5 (https=) | ||
| NZ590987A (en) | Quinuclidine carbonate derivatives and medicinal composition thereof | |
| MX2009000999A (es) | Derivados de quinuclidina como antagonistas de m3. | |
| JP2005525322A5 (https=) | ||
| MX377387B (es) | Nuevo compuesto para usarse en el tratamiento de fibrosis quística. | |
| EP4591936A3 (en) | Treatment of respiratory diseases | |
| JP2013538857A5 (https=) | ||
| JP2015509075A5 (https=) | ||
| HRP20151338T1 (hr) | [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoksi-etil)-4trifluorometoksi-1h-indol-3-il]metanon kao inhibitor triptaze mastocita | |
| SG10201806681YA (en) | Amide compound and use thereof as agent for the treatment and prevention of diseases caused by rna- and/or dna-containing viruses, and concomitant diseases | |
| JOP20200314A1 (ar) | تركيبات صيدلانية مستقرة لأجهزة إستنشاق جرعات مضغوطة معايرة الجرعة | |
| JP2016529315A5 (https=) |